Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P10 versus Rituxan in low tumor burden follicular lymphoma
2014-005324-10Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Celltrion. Primary endpoint: Overall response rate at 7 months. Started Jun 2015; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2014-005324-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005324-10.